Association between MTHFR variant and diabetic neuropathy

Pharmacol Rep. 2018 Feb;70(1):1-5. doi: 10.1016/j.pharep.2017.04.017. Epub 2017 Apr 26.

Abstract

Background: Methylene-tetrahydrofolate reductase (MTHFR) gene variant may play an important role in the pathophysiology of diabetes and its complications due to its influence on plasma homocysteine levels and also its effect on scavenging peroxynitrite radicals. Diabetic peripheral neuropathy (DPN) is one of the most common diabetic chronic complications. The aim of this study was to investigate the relationship between diabetic neuropathy and MTHFR gene C677T and 1298A ⁄C polymorphisms.

Method: Patients with type 2 diabetes N=248 were enrolled in the study, consisting of patients with neuropathy (N=141) and patients without neuropathy (N=107). MTHFR C677T polymorphism was analyzed using polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) of genomic DNA for genotyping of samples. 1298A/C polymorphism was evaluated using ARMS-PCR.

Result: There was a significant difference in MTHFR polymorphism between the groups with and without neuropathy.

Conclusion: Our results suggest that MTHFR 677 variant confer risk for diabetic neuropathy among Iranian patients with type 2 diabetes.

Keywords: Diabetic neuropathy; MTHFR; Polymorphism.

MeSH terms

  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / enzymology
  • Diabetes Mellitus, Type 2 / genetics*
  • Diabetic Neuropathies / diagnosis
  • Diabetic Neuropathies / enzymology
  • Diabetic Neuropathies / genetics*
  • Female
  • Gene Frequency
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Humans
  • Iran
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Phenotype
  • Polymorphism, Genetic*
  • Risk Factors

Substances

  • MTHFR protein, human
  • Methylenetetrahydrofolate Reductase (NADPH2)